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Abstract
Background:  Elucidating the molecular mechanisms by which tumors become resistant to
Herceptin is critical for the treatment of Her2-overexpressed metastatic breast cancer.
Methods: To further understand Herceptin resistance mechanisms at the molecular level, we used
comparative proteome approaches to analyze two human breast cancer cell lines; Her2-positive
SK-BR-3 cells and its Herceptin-resistant SK-BR-3 (SK-BR-3 HR) cells.
Results: Heat-shock protein 27 (HSP27) expression was shown to be upregulated in SK-BR-3 HR
cells. Suppression of HSP27 by specific siRNA transfection increased the susceptibility of SK-BR-3
HR cells to Herceptin. In the presence of Herceptin, Her2 was downregulated in both cell lines.
However, Her2 expression was reduced by a greater amount in SK-BR-3 parent cells than in SK-
BR-3 HR cells. Interestingly, co-immunoprecipitation analysis showed that HSP27 can bind to Her2.
In the absence of Herceptin, HSP27 expression is suppressed and Her2 expression is reduced,
indicating that downregulation of Her2 by Herceptin can be obstructed by the formation of a Her2-
HSP27 complex.
Conclusion: Our present study demonstrates that upregulated HSP27 in human breast cancer
cells can reduce Herceptin susceptibility by increasing Her2 protein stability.
Background
The epidermal growth factor receptor (EGFR)-related tyro-
sine kinase Her2 is an important therapeutic target in
breast cancer. Herceptin is active against Her2-overex-
pressing metastatic breast cancers. However, the objective
response rates to Herceptin monotherapy are low, with
median 9-month response rates ranging from 12–34%
[1]. At present, Herceptin is administered in combination
with chemotherapies involving paclitaxel or docetaxel,
which increase response rates, time to disease progression,
and overall survival compared with Herceptin mono-
therapy. However, most patients who achieve an initial
response to Herceptin-based regimens generally acquire
resistance within 1 year [2-6].
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Determining the molecular mechanisms by which tumors
become resistant to Herceptin-mediated cytotoxicity is
critical to improving the survival of metastatic breast can-
cer patients with tumors that overexpress Her2. Numer-
ous efforts have been made to identify the mechanisms
underlying Herceptin resistance [see reviews [7] and [8]].
For example, Her2 mutations or low Her2 expression lev-
els reduced the interaction between Her2 and Herceptin,
and led to increased compensatory signaling from other
Her receptors [9-11]. However, our understanding of Her-
ceptin resistance remains limited.
In the present study we sought to further our understand-
ing of Herceptin resistance mechanisms at the molecular
level. The biological impact of overexpressed heat-shock
protein 27 (HSP27) in the human breast cancer cell line
SK-BR-3 with Herceptin resistance (SK-BR-3 HR) is dis-
cussed.
Methods
Human breast cancer cell lines
The human breast cancer cell lines SK-BR-3, AU565,
HCC1569, HCC70, and MCF7 were obtained from the
American Type Culture Collection (ATCC, Manassas, VA).
The Herceptin-resistant human breast cancer cell line
JIMT-1 was purchased from the German Collection of
Microorganisms and Cell Cultures (Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmbH, Braun-
schweig, Germany). SK-BR-3 HR cells, which are resistant
to Herceptin (Genentech, Inc., South San Francisco, CA),
were spontaneously derived from SK-BR-3 cells by
increasing the generation-to-generation passage.
Genotyping of SK-BR-3 and its Herceptin-resistant-
derivative cell line, SK-BR-3 HR
The total amount of genomic DNA was extracted using the
TRI reagent according to the manufacturer's instructions
(Molecular Research Center, Cincinnati, OH, USA). PCR
amplification was performed using the AmpFlSTR Pro-
filer™ PCR Amplification Kit (Applied Biosystems, Oster
City, CA) to amplify the D3S1358, vWA, FGA, amelo-
genin, TH01, TPOX, CSF1PO, D5S818, D13S317, and
D7S820 loci in sample genomic DNA. PCR assays were
performed according to the manufacturer's recommenda-
tions except that the PCR volume was 50 μL and con-
tained 2 ng of template DNA. The PCR conditions were
95°C for 11 minutes, followed by 28 cycles at 94°C for 1
minute, 59°C for 1 minute, and 72°C for 1 minute. A
final extension was conducted at 60°C for 45 minutes,
and the products were then maintained at 25°C. Separa-
tion and detection of the amplified product was per-
formed using an ABI 3730 Genetic Analyser (Applied
Biosystems) with GeneScan 2.1 and Genotyper 2.0 soft-
ware.
3- [4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide (MTT) assay
A colorimetric assay using the tetrazolium salt MTT was
used to assess cell proliferation after HSP27 suppression.
MTT assays were performed as described in a previous
report [12]. Briefly, 0.18 mL cultures containing equal
numbers of cells were incubated in each well, to which
0.02 mL of 10 × Herceptin (Genentech, Inc.) or phos-
phate-buffered saline (PBS, an untreated 100% survival
control) was added. After 4 days of culture, 0.1 mg of MTT
was added to each well, and incubated at 37°C for a fur-
ther 4 hours. Plates were centrifuged at 450 × g for 5 min-
utes at room temperature and the supernatant was
removed. Dimethyl sulfoxide (0.15 mL) was added to
each well to solubilize the crystals, and the plates were
immediately read at 540 nm using a scanning multiwell
spectrometer (Bio-Tek instruments Inc., Burlington, VT).
All experiments were performed three times, and the IC50
(μg/mL) values are presented as means ± standard devia-
tion.
Western-blot analysis
Western-blot analysis was performed as described previ-
ously [12]. Briefly, cell homogenates containing equiva-
lent amounts of protein were centrifuged at 4,000 × g, and
the supernatant fractions were separated by SDS-PAGE.
Following electrophoresis, the proteins were transferred
to polyvinylidene fluoride (PVDF) membranes (Milli-
pore, Bedford, USA) blocked by incubation for 2 hours at
4°C in 1% Tween 20-TBS buffer containing 1.5% non-fat
dry milk (Bio-Rad, Richmond, USA) and 1 mM of MgCl2.
Membranes were incubated for 2 hours at room tempera-
ture with primary antibodies against Her2 (Dako, Glos-
trup, Denmark), HSP27 (Abcam, Cambridgeshire, UK),
fibrillarin (Abcam), or actin (Sigma, St Louis, MO). Mem-
branes were washed three times with blocking solution,
for 15 minutes at a time, and incubated with diluted
horseradish-peroxidase (HRP)-conjugated secondary
antibody (Southern Biotech, Birmingham, AL) for 1 hour
at room temperature. This was followed by washing with
blocking solution (3 × 15 minutes), incubation with
WEST-ZOL®  plus chemiluminescence reagent (iNtRON
Biotechnology, Gyeonggi, Korea) for 1 minute, and expo-
sure to film (Kodak Blue XB-1, Rochester, NY).
2-DE
Two-dimensional electrophoresis (2-DE) analysis was
performed as previously described [12]. Briefly, 0.15 mg
protein samples were applied to 13 cm immobilized pH
3–10 non-linear gradient strips (Pharmacia Biotechnol-
ogy, Uppsala, Sweden). Proteins were focused at 8,000 V
within 3 hours. The second-dimension separation
involved 12% polyacrylamide gels (chemicals from Serva,
Heidelberg, Germany and Bio-Rad, Hercules, CA). 2-DE
gels were stained with Colloidal Coomassie Blue (Invitro-BMC Cancer 2008, 8:286 http://www.biomedcentral.com/1471-2407/8/286
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gen, Carlsbad, CA) for 24 hours and were then destained
with deionized water.
Matrix-assisted laser desorption ionization-mass 
spectrometry (MALDI-MS) and database searching
Sections of 2-DE gels containing proteins of interest were
excised, destained with 50% acetonitrile in 0.1 M ammo-
nium bicarbonate, and dried in a SpeedVac evaporator.
Dried gel pieces were reswollen with 30 μL of 25 mM
sodium bicarbonate at pH 8.8, containing 50 ng of trypsin
(Promega, Madison, WI) at 37°C overnight. α-Cyano 4
hydroxycinnamic acid (20 mg) (Bruker Daltonics,
Bremen, Germany) was dissolved in 1 mL acetone:etha-
nol (1:2, v/v), and 0.5 μL of the matrix solution was mixed
with an equivalent volume of the sample. Analysis was
performed using an Ultraflex TOF/TOF system (Bruker
Daltonics).
The Ultraflex TOF/TOF system was operated in the posi-
tive-ion-reflect mode. Each spectrum was the average of
250–450 laser shots. Mass spectra were first calibrated in
the closed external mode using the peptide calibration
standard II (Bruker Daltonics), and sometimes also in the
internal statistical mode to achieve maximum calibration
mass accuracy, and then analyzed with FlexAnalysis soft-
ware, version 2.4 (Bruker Daltonics). Peptide mass peaks
from each spectrum were analyzed by the Mascot peptide
mass fingerprinting search tool http://www.matrix sci-
ence.com using BioTools software, version 3.0 (Bruker
Daltonics).
The search included peaks with a signal-to-noise (S/N)
ratio greater than 3. The peak list for each sample was
compared with the non-redundant Mass Spectrometry
Protein Sequence Database (MSDB) for protein identifica-
tion. Standard settings included the following: enzyme,
trypsin; missed cleavage, one; fixed modifications, none
selected; variable modifications, oxidized methionine;
protein mass, blank; mass values, MH+ (mono-isotopic);
mass tolerance, between 75 and 100 ppm.
Subcellular fractionation
Nuclear fractions of cells were isolated from cytoplasm
using the nuclei isolation kit 'Nuclei PURE Prep' (Sigma-
Aldrich, St Louis, MO), as recommended by the manufac-
turer. Membrane fractionation was performed as
described previously with the following modifications
[13]. Briefly, cells were vortexed vigorously for 5 min in
cold lysis buffer containing 40 mM of Tris and 150 U/mL
of benzonase, and then homogenized on ice. Vortexing
and homogenization were repeated. The cell homogenate
was centrifuged at 12,000 × g for 10 min at room temper-
ature. The insoluble pellet was washed twice with lysis
buffer and resuspended in membrane fractionation buffer
containing 5 M urea, 2 M thiourea, 2% w/v CHAPS, 40
mM Tris and 100 mM DTT. The vortexing, homogeniza-
tion and centrifugation process was then repeated. The
supernatant was collected as the membrane fraction.
Immunoprecipitation
All procedures were performed at 4°C unless otherwise
specified. Approximately 107 cells in 1 ml of cold 1 × RIPA
buffer containing protease inhibitors (Roche Diagnostics)
were incubated on ice for 30 minutes with occasional mix-
ing. Cell lysates were centrifuged at 12,000 × g for 10 min-
utes, and the supernatants were collected without
disturbing the pellet. The supernatants were mixed with
primary antibodies against Her2 (Dako) and HSP27
(Abcam), and incubated for 2 hours on a rocking plat-
form. Prepared protein G sepharose beads (100 μL) (GE
Health Care Life Sciences) were added and were further
incubated on ice for 1 hour on a rocking platform. The
mixture was centrifuged at 10,000 × g for 30 seconds, and
the supernatant was then completely removed. Protein G
sepharose beads were washed five times with 1 mL of cold
1 × RIPA to minimize the background. Next, 100 μL of 2
× SDS sample buffer was added to the bead pellet, and the
mixture was heated at 100°C for 10 minutes. After boil-
ing, immunoprecipitates were centrifuged at 10,000 × g
for 5 minutes, and the supernatants were collected for
Western-blot analyses.
siRNA synthesis and transfection
Validated siRNA (Cat No. SI00300496) against HSP27
and non-silencing (NS) control siRNA (5'-AATTCTC-
CGAACGTGTCACGT-3') were obtained from Qiagen,
Chatsworth, CA. Transfection with siRNAs was performed
using HiferFect transfection reagent (Qiagen), according
to the manufacturer's instructions. Briefly, 2 μL of 20 μM
siRNA solution and 20 mL of the transfection reagent
were incubated in 100 mL of serum-free RPMI 1,640
medium for 10 minutes to facilitate complex formation.
The resulting mixture (final concentration of 5 nM) was
added to the Herceptin-resistant SK-BR-3 (4 × 105), and
incubated in a 60 mm tissue culture dish with 4 mL RPMI
1640.
Results
Establishment of SK-BR-3 HR, a human breast cancer cell 
line with Herceptin resistance
The Human breast cancer cell line SK-BR-3 was cultured
according to the ATCC instructions, and the derivative cell
line from SK-BR-3 with reduced Herceptin susceptibility
was generated spontaneously by increasing generation-to-
generation passage. Microscopy images in Fig. 1a show
increased proliferation of the Herceptin-resistant SK-BR-3
derivative cell line (SK-BR-3 HR) in the presence of Her-
ceptin. Increased proliferation of SK-BR-3 HR cells in the
presence of Herceptin was confirmed by the MTT time-
course assay (Fig. 1b). However, these two cell lines, par-BMC Cancer 2008, 8:286 http://www.biomedcentral.com/1471-2407/8/286
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Establishment of human breast cancer cell line SK-BR-3 with Herceptin resistance Figure 1
Establishment of human breast cancer cell line SK-BR-3 with Herceptin resistance. (a) Microscopy images showing 
increased cell proliferation of the SK-BR-3 derivative cell line SK-BR-3 HR in the presence of Herceptin. (b) Differential prolif-
eration rate of SK-BR-3 HR in the presence of Herceptin. Data are means ± standard deviations of three independent experi-
ments. (c) Genotyping of SK-BR-3 and SK-BR-3 HR, showing the two cell lines have the same genetic identity.BMC Cancer 2008, 8:286 http://www.biomedcentral.com/1471-2407/8/286
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ent SK-BR-3 and the Herceptin-resistant SK-BR-3 HR, are
genetically identical (Fig. 1c).
Identification of overexpressed HSP27 in SK-BR-3 HR
To verify the differential protein expression between the
SK-BR-3 and SK-BR-3 HR cell lines, total proteins were
isolated from SK-BR-3 and SK-BR-3 HR cells and subjected
to 2-DE. A strongly stained protein spot from SK-BR-3 HR
cells (enlarged partial 2-DE gels on Fig. 2a) was in-gel
digested for MALDI-MS analysis, and shown to be human
HSP27 (Fig. 2b). Increased levels of HSP27 in SK-BR-3 HR
cells were confirmed by Western-blot analysis (Fig. 2c).
However, there were no differences in Her2 expression
between the two cell lines (Fig. 2c, d). The subcellular lev-
els of HSP27 and Her2 were investigated in seven human
breast cancer cell lines, including SK-BR-3 and SK-BR-3
HR (Fig. 2d). Most HSP27 was localized in the cytoplasm
of the breast cancer cell lines tested. However, there was
no correlation between Herceptin susceptibility in breast
cancer cell lines and HSP27 expression (Fig. 2d). HSP27
expression in JIMT-1, which is a cell line that has previ-
ously been reported to be Herceptin resistant, was lower
than in SK-BR-3 HR (Fig. 2d).
Increased susceptibility of SK-BR-3 HR to Herceptin after 
suppression of HSP27
SK-BR-3 HR was transfected with siRNA against HSP27
(Fig. 3a), and the proliferation of cells was assessed (Fig.
3b). At 96 hours after transfection in the presence of Her-
ceptin, the level of HSP27 expression was decreased to
about 55% the original level, and the rate of cell prolifer-
ation was about 65% of that for controls transfected with
buffer only or non-silencing (NS) siRNAs (Fig, 3b, lower
panel).
Effect of Herceptin on the levels of HSP27 and Her2 
protein
Compared with the SK-BR-3 HR cells, there were signifi-
cant reductions in Her2 expression in SK-BR-3 parent cells
after treatment with Herceptin (Fig. 3c, left panel). The
levels of HSP27 were essentially not changed by the Her-
ceptin treatment (Fig. 3c, right panel).
Interaction of HSP27 with Her2 and its effect on Her2 
stability
To test the interaction between HSP27 and Her2, immu-
noprecipitate of the anti-Her2 antibody was proved by the
anti-HSP27 antibody, and vice versa (Fig. 4a). Immunore-
active signals of Her2 and HSP27 were clearly detected in
the immunoprecipitates of anti-HSP27 and anti-Her2,
respectively (Fig. 4a). Without treatment of Herceptin, the
HSP27 in SK-BR-3 HR was suppressed, and the level of
Her2 was compared to that of the controls transfected by
either buffer only or NS siRNA (Fig. 4b). In the absence of
Herceptin, the Her2 protein level was not affected by
siRNA transfection conditions, but HSP27 suppression
was accompanied by a decrease in the Her2 protein level
(Fig. 4b). However, in the presence of Herceptin Her2 pro-
tein was decreased not only in cells transfected by HSP27
siRNA but also in the controls (Fig. 4c).
Discussion and conclusion
In the present study, to understand Herceptin-resistance
mechanisms in human breast cancer cells, the Herceptin-
resistant human breast cancer cell line SK-BR-3 HR was
generated from the parent cell line SK-BR-3 (Fig. 1). Com-
parative proteomic analyses of these two cell lines
revealed that HSP27 expression was upregulated in SK-
BR-3 HR cells (Fig. 2). HSPs are known to play important
roles in folding, intracellular localization, and degrada-
tion of cellular proteins, but the cellular role of HSP27 in
cancers is not yet completely understood. Recently, there
have been reports that high HSP27 expression levels are
associated with a poor prognosis for specific cancers
including gastric, liver, and prostate carcinomas, and oste-
osarcomas [see the review, [14]]. Furthermore, expression
of HSP27 in primary breast cancers is associated with a
short survival for node-negative patients, and increased
HSP27 expression levels have been found in highly meta-
static variant breast cancer cells [15,16]. However, osteo-
lytic bone metastases of human breast cancer cells are
reduced by HSP27 overexpression [17].
In addition to being a clinicopathological factor, upregu-
lated HSP27 expression has also been proposed to be pre-
dictive of poor response to some anticancer treatments for
breast cancer, non-small cell lung cancer, and bladder
cancer [14,18-20]. For example, HSP27 overexpression
inhibits doxorubicin-induced apoptosis in human breast
cancer cells [21]. However, increased levels of HSP27
expression were not significantly associated with response
to tamoxifen, time to treatment failure, or survival in an
estrogen-receptor-positive breast cancer population [22].
HSP27 is highly expressed in Her2-positive tumors [23].
HSP27 is one of the downstream effectors of p38 MAP
kinase-mediated matrix metalloproteinase type 2 activa-
tion and is a modulator of Stat3-regulated apoptosis
[24,25]. Ser78 phosphorylation of HSP27 is mainly regu-
lated by the Her2-p38 MAPK pathway, and is significantly
correlated with Her2- and lymph-node positivity [23].
Phosphorylation of HSP27 may play a role in the
response of breast cancer cells to the anticancer drug [26].
However a detailed understanding of the role of HSP27 in
Herceptin-resistance mechanisms has yet to be achieved.
Our present results provide further evidence to support
the involvement of HSP27 in Herceptin resistance in
human breast cancer cells (Fig. 3). Changes in the prolif-
eration rate of SK-BR-3 cells with different HSP27 levels
may provide a clue. Previous studies have reportedBMC Cancer 2008, 8:286 http://www.biomedcentral.com/1471-2407/8/286
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Identification of HSP27 overexpressed in SK-BR-3 HR Figure 2
Identification of HSP27 overexpressed in SK-BR-3 HR. (a) Typical pattern of two-dimensional (2-DE) gel electrophore-
sis analysis of SK-BR-3 and SK-BR-3 HR cells. (b) Identification of HSP27 by MALDI-MS analysis. The protein spot indicated in 
the enlarged image in Figure 2A was in-gel-digested by trypsin and subjected to MALDI-MS analysis. The protein was identified 
as human HSP27. (c) Western-blot analysis to confirm overexpressed HSP27 in SK-BR-3 HR cells. (d) Subcellular levels of 
HSP27 and Her2 in seven individual human breast cancer cell lines.BMC Cancer 2008, 8:286 http://www.biomedcentral.com/1471-2407/8/286
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Effects of suppressed HSP27 on the susceptibility of SK-BR-3 HR to Herceptin Figure 3
Effects of suppressed HSP27 on the susceptibility of SK-BR-3 HR to Herceptin. (a) Suppressed HSP27 after transfec-
tion with siRNAs in the presence of Herceptin. (b) MTT analysis showed increased Herceptin susceptibility of SK-BR-3 HR 
after HSP27 suppression. (c) Effect of Herceptin on the levels of Her2 and HSP27. Altered total levels of HSP27 and Her2 by 
Herceptin treatment. Treatment of Herceptin led to reductions in HSP27 and Her2 levels in the homogenates of SK-BR-3 and 
SK-BR-3 HR cells. Data (a, b, c) are means ± standard deviations of three independent experiments.BMC Cancer 2008, 8:286 http://www.biomedcentral.com/1471-2407/8/286
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Interactions between HSP27 and Her2, and reduced Her2 levels after HSP27 suppression Figure 4
Interactions between HSP27 and Her2, and reduced Her2 levels after HSP27 suppression. (a) Western-blot anal-
ysis of immunoprecipitates of anti-Her2 and anti-HSP2 antibodies. (b) Reduced Her2 levels associated with HSP27 suppression. 
(c) Reduced levels of Her2 in control and HSP27-suppressed cells in the presence of Herceptin. Data (b, c) are means ± stand-
ard deviations of three independent experiments.BMC Cancer 2008, 8:286 http://www.biomedcentral.com/1471-2407/8/286
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reduced proliferation levels of the human breast cancer
cell line MDA-MB-231 and the human laryngeal cancer
cell line Hep-2 after transfection with an HSP27-overex-
pressing vector [27,28]. In agreement with these results,
we found a slow proliferation rate of SK-BR-3 HR with
upregulated HSP27 (Fig. 1b, upper panel). A decreased
proliferation rate was observed after HSP27 suppression
in the presence of Herceptin, but HSP27 suppression
alone did not affect the rate of cell proliferation (Fig. 3b).
A slow proliferation rate of cancer cells is known to be a
mechanism to minimize the effects of anticancer agents,
so overexpression of HSP27 may reduce the Herceptin
susceptibility of human breast cancer cells by affecting the
proliferation rate [29-31].
Her2 expression was shown to be downregulated in the
presence of Herceptin in two different human breast can-
cer cell lines, SK-BR-3 (Fig. 3c) and MDA453 [32]. Degra-
dation of the Her2 protein has been proposed as a
mechanism by which Herceptin acts on Her2-positive
breast cancer cells [8]. Our present results are an interest-
ing example of how Her2 levels are affected by Herceptin
(Fig. 3c, left panel). In the presence of Herceptin, there
were greater reductions in the levels of Her2 in SK-BR-3
cells compared with SK-BR-3 HR cells (Fig. 3c, left panel),
even though there was no mutation in the Her2 gene in
either cell line (data not shown). Our results also indicate
that Herceptin-induced reductions in Her2 levels can be
minimized in SK-BR-3 HR cells. Immunoprecipitation
analysis of the interaction between Her2 and HSP27 dem-
onstrated the binding capacity of HSP27 to Her2 (Fig. 4a).
Protein-protein binding can often increase protein stabil-
ity and upregulated HSP27 expression levels have been
reported in Her2-positive breast tumors [33]. Therefore,
we hypothesized that HSP27 may stabilize Her2. Interest-
ingly, suppression of HSP27 was associated with reduc-
tions in Her2 levels in the absence of Herceptin (Fig. 4b).
It is still not clear whether HSP27 can interact with Her2
at different subcellular locations. However, both mole-
cules were detected not only in the cytoplasm but also in
the nucleus (Fig. 2d), suggesting that Her2 may be stabi-
lized by interaction with HSP27 regardless of subcellular
localization. Overall, our findings indicate that upregula-
tion of HSP27 can make SK-BR-3 HR cells less sensitive to
Herceptin by minimizing the Herceptin-induced Her2
degradation.
In conclusion, our findings demonstrate that upregula-
tion of HSP27 in human breast cancer cells can reduce
Herceptin susceptibility by increasing Her2 protein stabil-
ity. The development of specific agents to block HSP27
may overcome Herceptin resistance and improve the sur-
vival of breast cancer patients [34].
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